Literature DB >> 26970252

L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.

Liang Li1, Siping Sun2, Thaigarajan Parumasivam2, John A Denman3, Thomas Gengenbach4, Patricia Tang2, Shirui Mao5, Hak-Kim Chan6.   

Abstract

L-Leucine (LL) has been widely used to enhance the dispersion performance of powders for inhalation. LL can also protect powders against moisture, but this effect is much less studied. The aim of this study was to investigate whether LL could prevent moisture-induced deterioration in in vitro aerosolization performances of highly hygroscopic spray-dried powders. Disodium cromoglycate (DSCG) was chosen as a model drug and different amounts of LL (2-40% w/w) were added to the formulation, with the aim to explore the relationship between powder dispersion, moisture protection and physicochemical properties of the powders. The powder formulations were prepared by spray drying of aqueous solutions containing known concentrations of DSCG and LL. The particle sizes were measured by laser diffraction. The physicochemical properties of fine particles were characterized by X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapor sorption (DVS). The surface morphology and chemistry of fine particles were analyzed by scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS), and time-of-flight secondary ion mass spectrometry (ToF-SIMS). In vitro aerosolization performances were evaluated by a next generation impactor (NGI) after the powders were stored at 60% or 75% relative humidity (RH), and 25°C for 24h. Spray-dried (SD) DSCG powders were amorphous and absorbed 30-45% (w/w) water at 70-80% RH, resulting in deterioration in the aerosolization performance of the powders. LL did not decrease the water uptake of DSCG powders, but it could significantly reduce the effect of moisture on aerosolization performances. This is due to enrichment of crystalline LL on the surface of the composite particles. The effect was directly related to the percentage of LL coverage on the surface of particles. Formulations having 61-73% (molar percent) of LL on the particle surface (which correspond to 10-20% (w/w) of LL in the bulk powders) could minimize moisture-induced deterioration in the aerosol performance. In conclusion, particle surface coverage of LL can offer short-term protection against moisture on dispersion of hygroscopic powders.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disodium cromoglycate; Dry powder inhalers; Fine particle fraction; Moisture protection; Spray drying; l-Leucine

Mesh:

Substances:

Year:  2016        PMID: 26970252     DOI: 10.1016/j.ejpb.2016.02.010

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  27 in total

1.  Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599.

Authors:  Ian E Stewart; Pradeep B Lukka; Jiuyu Liu; Bernd Meibohm; Mercedes Gonzalez-Juarrero; Miriam S Braunstein; Richard E Lee; Anthony J Hickey
Journal:  Pharm Res       Date:  2019-07-18       Impact factor: 4.200

2.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

3.  A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery.

Authors:  S Focaroli; P T Mah; J E Hastedt; I Gitlin; S Oscarson; J V Fahy; A M Healy
Journal:  Int J Pharm       Date:  2019-03-05       Impact factor: 5.875

4.  The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.

Authors:  Ahmadreza Barazesh; Kambiz Gilani; Mohammadreza Rouini; Mohammad Ali Barghi
Journal:  Daru       Date:  2019-12-05       Impact factor: 3.117

5.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

6.  Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.

Authors:  Nivedita Shetty; Heejun Park; Dmitry Zemlyanov; Sharad Mangal; Sonal Bhujbal; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-04-18       Impact factor: 5.875

7.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

8.  Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.

Authors:  Sharad Mangal; Jiayang Huang; Nivedita Shetty; Heejun Park; Yu-Wei Lin; Heidi H Yu; Dmitry Zemlyanov; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-02-21       Impact factor: 5.875

9.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

10.  Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.

Authors:  Rachel Y Chang; Jennifer Wong; Ash Mathai; Sandra Morales; Elizabeth Kutter; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2017-09-07       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.